Latest Car T News

Autosports Group is set to acquire ten Barry Bourke Motors dealerships in Victoria for $34 million, expanding its luxury automotive footprint and strengthening key manufacturer partnerships.

FSA Group Ltd reports robust growth in loan origination and loan pools, driven by car loans and asset finance, while raising profit guidance for FY2026. The company’s strategic focus on automation and offshore expansion underpins its ambitious $1.3 billion loan pool target.

Turners Automotive Group has posted a resilient and record first-half result for FY26, with net profit before tax up 13% despite ongoing economic challenges. The company’s diversified model and strategic capital moves underpin its confident outlook.

Webjet Group reports steady first-half results with a 16% rise in underlying profit and announces its inaugural fully franked interim dividend, signalling confidence despite a challenging travel market.

Plenti Group Limited has reported a remarkable half-year performance for FY26, with revenues up 20% and profit soaring over tenfold to $10.5 million. The fintech lender’s loan portfolio expanded 24%, driven by strong demand across automotive, renewable energy, and personal loans.

FleetPartners has acquired Remunerator, a seasoned salary packaging and novated lease provider, enhancing its product suite and market position in the leasing sector.

Chimeric Therapeutics reports promising interim results from its CHM CDH17 Phase 1/2 trial, with 75% disease control at 28 days and durable responses in gastrointestinal cancers.

Jumbo Interactive’s 2025 AGM highlighted solid early FY26 growth across its core segments alongside transformative acquisitions in the UK and US, prompting a cautious dividend policy revision to balance growth and debt reduction.

Streamplay’s Noodlecake Studios has signed a new publishing deal with Funselektor Labs to bring the motorsport management game Golden Lap to mobile devices, marking their third successful collaboration.

Chimeric Therapeutics has progressed its CHM CDH17 and CHM CORE-NK clinical trials with promising safety and efficacy signals, while securing a key manufacturing partnership and appointing a renowned haematologist to its board. However, the company faces a pressing cash runway challenge.

CL8 Holdings has finalized proceeds from its Carly Car Subscription sale, slashed expenses, and is actively pursuing new business opportunities despite a lean cash position.

Imugene Limited reports an 81% overall response rate in its azer-cel CAR T-cell therapy trial for difficult lymphomas, alongside a $25 million capital raise that extends its cash runway to mid-2027.